Kelly Dooley, MD, PhD

Faculty

Titles:

Assistant Professor, Medicine and Pharmacology and Molecular Sciences

Email:

kdooley1@jhmi.edu

SciVal:

SciVal Link

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

Categories

Events

«

April 2018

»
S
M
T
W
T
F
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
·
·
·
·
·

Projects

The role of cell wall lipids in pathogenesis...

This study will use a combination of transcriptional, lipidomic, genetic, and imaging techniques to investigate whether...

Read More

Understanding the role of repeat testing and...

We have developed a Markov model of serial IGRA testing to help improve testing algorithms with TST vs. IGRA in low-risk...

Read More

MDR TB treatment as prevention: modeling the...

We are using transmission modeling to evaluate the potential impact of expanding DST and access to MDR TB treatment in Vietnam,...

Read More

Assessing the social value of novel regimens...

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation...

Read More